Use lowest dose that will gradually increase hemoglobin level and avoid RBC transfusion)
Anemia of Chronic Renal Failure
Anemia Secondary to AZT Therapy
Anemia from Chemotherapy
(Use only for chemotherapy-related anemia and discontinue when chemotherapy course is completed)
Use Cautiously in:
CV: Hypertension (24%); deep venous thrombosis (DVT) (10%).
CNS: Fatigue (25%); dizziness, insomnia (21%); headache (19%); asthenia (13%); anxiety, paresthesia (11%); seizure.
DERM: Pruritus (22%); skin pain (18%); rash (16%).
GI: Nausea (58%); constipation (53%); vomiting (29%); diarrhea (21%); dyspepsia (11%).
GU: UTI (12%).
LOCAL: Skin reaction at injection site (29%).
MUSC: Arthralgia (11%); trunk pain (3%).
RESP: Cough (18%); congestion (15%); shortness of breath (14%); upper respiratory tract infection (11%).
OTHER: Pyrexia (51%); edema (17%); chest pain, clotted access (7%).
Therapeutic Classification: antianemics
Pharmacologic Classification: hormones
Absorption: Well absorbed after subcut administration.
Half-life: 4–13 hr.
Increase in reticulocytes
Copyright ©Nims Drugs2015. All rights reserved.
Powered by : web creation Nepal